MicroRNAs (miR) including miR-34a have been shown to regulate nuclear receptor, drugmetabolizing enzyme and transporter gene expression in various cell model systems. However, to what degree miRNAs affect pharmacokinetics (PK) at the systemic level remains unknown.
Introduction
MicroRNAs (miRNA or miR) are a family of short, noncoding RNAs (ncRNA) that govern various cellular processes through posttranscriptional regulation of target gene expression (Ambros, 2004) .
Recent studies have demonstrated that many miRNAs are able to modulate the expression of nuclear receptors, drug-metabolizing enzymes and transporters, and consequently alter cellular drug metabolism and disposition capacities (Yu, 2009; Ingelman-Sundberg et al., 2013; Yokoi and Nakajima, 2013; Yu et al., 2016) . As an example, miR-34a was shown to directly regulate hepatocyte nuclear factor 4α (HNF4α or NR2A1) (Takagi et al., 2010) , 9-cis retinoic acid receptor alpha (RXRα or NR2B1) (Oda et al., 2014) , and nuclear factor (erythroid-derived 2)-like 2 (Nrf2 or NFE2L2) (Huang et al., 2014) in a number of cell line models. In addition, a negative correlation between Cytochrome P450 3A4 (CYP3A4) and miR-34a levels in a set of human liver samples was also identified (Lamba et al., 2014) . Nevertheless, it is unknown to what levels miRNAs may affect pharmacokinetic (PK) properties of a drug in a whole body system.
As master regulators of gene expression behind disease development and progression, some miRNAs may serve as therapeutic targets or agents (Bader et al., 2010; Kasinski and Slack, 2011; Ho and Yu, 2016) . Among them, miR-34a is commonly downregulated in patient tumor tissues and acts as a tumor suppressor (see review (Bader, 2012) ). Therefore, miR-34a agents may be reintroduced into tumor cells to control tumor progression and metastasis. Recently, our group has bioengineered a chimeric miR-34a agent and demonstrated this biologic miR-34a prodrug is effective to suppress miR-34a target gene expression, inhibit human carcinoma cell proliferation and invasion, and reduce tumor growth in subcutaneous and orthotopic xenograft mouse models This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on March 2, 2017 as DOI: 10.1124/dmd.116.074344 at ASPET Journals on October 20, 2017 dmd.aspetjournals.org Downloaded from Zhao et al., 2015; Zhao et al., 2016) . However, it is unknown if therapeutic miR-34a would cause significant drug-drug interactions (DDI), which is a critical component in drug development, particularly for combination therapy.
A robust and relevant in vivo system is warranted for assessing PK DDI, rather than predictions using in vitro data. However, preclinical PK DDI studies have largely been limited to the use of larger animal species, such as rats, canines, and non-human primates. A major barrier to the use of mice for PK studies is attributable to the need for large volumes of blood collected at a sufficient number of individual time points to construct a robust, single-animal plasma drug concentrationtime curve. As such, the use of mice in PK DDI studies has traditionally been limited to a "giant rat" approach, where individual mice are bled only at one to three time points and thus different mice are utilized to generate a complete blood drug concentration-time profile for naïve-pooled population PK analysis and modeling (Granvil et al., 2003; Shen et al., 2011; Jiang et al., 2013 ).
This method is valid given a robust analytical technique; however, intra-individual variability may manifest in exacerbated inter-animal variation in the PK profile and estimated PK parameters, ultimately compromising statistical power.
To delineate the potential effects of miR-34a on PK of co-administered drugs or possible DDIs, we first established a new practical single-mouse PK approach, requiring only simple manual blood microsampling via mouse tail vein coupled to a sensitive and accurate LC-MS/MS assay.
This LC-MS/MS assay allowed simultaneous quantification of five major CYP probe drugs and corresponding metabolites in minimal sample matrix. Complete plasma drug concentration-time curves in mice were thus successfully constructed and used for PK analyses. The validity and This article has not been copyedited and formatted. The final version may differ from this version. was purchased from BioreclamationIVT (Baltimore, MD). Sterile phosphate buffered saline (PBS, pH 7.4) was purchased from Gibco (Grand Island, NY). LC-MS grade acetonitrile (ACN), methanol, and formic acid were purchased from Fisher Scientific (Fair Lawn, NJ). In vivo jet-PEI was purchased from Polyplus-transfection (Illkirch, France).
The CYP probe substrate cocktail consisted of MDZ, PHE, DXM, DIC, and CLZ, and the stock solutions were dissolved in dimethyl sulfoxide. An appropriate dosing formulation was prepared by diluting the stock solutions into PBS for a dosage volume of 0.6 ml/30 g body weight and specific dose of 1.0 mg/kg MDZ, 2.8 mg/kg PHE, 26 mg/kg DXM, 3.25 mg/kg DIC, and 6.5 mg/kg
CLZ.
This article has not been copyedited and formatted. The final version may differ from this version. Expression and Purification of RNA Agents. Recombinant miR-34a prodrug and the control tRNA/methionine-sephadex aptamer (tRNA/MSA) were prepared as previously described . Briefly, competent HST08 Escherichia coli were transformed with appropriate plasmids and following a 12-h incubation at 37 ℃, bacteria were pelleted, resuspended, lysed in phenol to extract total RNA, and precipitated with salt and ethanol. Target RNA was isolated from total RNAs by anion exchange fast protein liquid chromatography (FPLC) method using a NGC FPLC System (BioRad, Hercules, CA), and its purity (> 99%, data not shown) was verified by a HPLC assay . Mice were administered intraperitoneally (i.p.) with either KTZ (50 mg/kg) or -NF (100 mg/kg) or vehicle (corn oil) (6 mice per group) to assess the impact of CYP inhibitor on probe drug PK.
Animals
After 1 h, mice were given CYP probe substrate cocktail by oral gavage (p.o.) at specific doses outlined above. Immediately following cocktail administration, manual microsampling was conducted at the following time points : 3, 10, 20, 30, 45, 50, 90, 120 , and 180 min. Specifically, a small volume of blood (10-20 l) was collected by carefully inserting a 28-gauge needle pre-coated with 6% EDTA into the lateral tail vein of a mouse restrained by a mouse holder during blood collection (Figure 1 ), mice were returned to their cages in between sampling time points. Mice were euthanized right after the experiment, and separate batches of mice were used for KTZ, -NF and vehicle treatment groups. Blood was then transferred into a 1.5 ml microcentrifuge tube containing 1 l of 6% EDTA, and centrifuged at 5,000 rpm and 4 0 C for 10 min. Plasma was transferred into a clean microcentrifuge tube, and stored at -80 0 C until LC-MS/MS quantification.
Likewise, different batches of mice were used to examine CYP inducer (6 mice per group) on the PK of CYP probe drugs, which were administered i.p. with either PCN (40 mg/kg), 3-MC (50 mg/kg), or vehicle (corn oil) once daily for 3 days. Cocktail administration and blood collection
were conducted 24 h after the treatment with CYP inducer or vehicle and was conducted in the same manner as the inhibition study.
To assay the effects of miR-34a on systemic pharmacokinetics, a paired study design was followed using a separate cohort of mice which would improve statistical power. Mice were first administered i.v. with in vivo-jetPEI-formulated tRNA/MSA (15 g of RNA, daily for four consecutive days). 24 h after the last dose of RNA agent, mice were treated with the CYP probe drug cocktail and blood samples were collected as described above. Following a two week washout and recovery period (U. S. Department of Health and Human Services, 2015) , the same mice were injected with miR-34a prodrug using the same dose and regimen, followed by the PK study.
To examine the levels of miR-34a accumulation in mouse liver and impact on hepatic drugmetabolizing capacity, a separate batch of male CD-1 mice were administered either miR-34a agent or negative control (tRNA/MSA) using the same dosing scheme as described above. 24 h 90% B for 2 min before returned to initial condition for 3 min. In negative ion model (ESI-) for the analyses of CLZ, DIC and corresponding metabolites, column was eluted with 10% B for 1 min, which was increased to 52% B over 2.5 min, held at 52% B for 1.5 min, and then held at 90%
B for 1 min before returned to initial conditions for 3 min.
Analytes were detected and quantified by multiple reaction monitoring (MRM) using an AB Sciex 4000 QTRAP tandem mass spectrometry system (AB Sciex, Framingham, MA) under an optimal condition: ion spray voltage of 5.4 kV, desolvation temperature of 500 0 C curtain gas pressure of 30 psi, nebulizer and turbo gas pressures of 50 psi, and entrance potential of 10 V. Specific MS conditions for individual MRMs were optimized and are listed in Table 1 . Each analyte peak area was normalized to the internal standard (harmaline for ESI+ analytes, and warfarin for ESIanalytes). Calibration curve was generated for each analyte using Analyst software (Version 1.6.2, AB Sciex). The accuracy and precision were further validated. In addition, following data analysis, analyte concentrations in a few test samples were revealed to be above the calibration ranges, which were accurately re-quantified after diluting the original plasma samples in blank CD-1 mouse plasma.
RNA Isolation and Quantification of pre-miR-34a and Mature miR-34a. Total RNA was isolated using Direct-zol RNA kit (Zymo Research, Irvine, CA), following the manufacturer's instructions. cDNA was generated by reverse transcription and levels of precursor and mature miR-34a were quantitated by corresponding selective real-time quantitative PCR assays on a CFX96 Touch real-time PCR system (Bio-Rad), as described previously . Cycle
This article has not been copyedited and formatted. The final version may differ from this version. thresholds for precursor and mature miR-34a were determined by regression, normalized to U6 small nucleolar RNA, and then to control using the 2 -ΔΔCt formula. samples and time points to determine enzymatic specificity and microsomes quality. The mixture was vortexed and centrifuged at 10,000 g for 10 min. 3 mL of supernatant was decanted and dried over air, and the residue was reconstituted with 100 L of 20% methanol. Levels of parent drugs and specific metabolites were quantitated using the LC-MS/MS methods described above.
Mouse Liver Microsomes Preparation and
Pharmacokinetics Modeling. Pharmacokinetic data analyses were conducted using a non- (Vz/F). In vitro substrate depletion data were fit to a mono-exponential decay model (or biphasic decay for MDZ). In vitro intrinsic clearance (CLint) was calculated using the equation CLint = A0/AUC0→∞.
Statistical Analysis.
Values are means ± standard deviation. Drug and metabolite concentration versus time curves were compared for different treatments using two-way ANOVA and Bonferroni post-tests (GraphPad Prism, San Diego, CA). PK parameters were further compared using oneway ANOVA and Bonferroni post-tests. Difference was considered as statistically significant when the probability was less than 0.05 (p < 0.05).
This article has not been copyedited and formatted. The final version may differ from this version. was found to be a practical means to manual microsampling, yielding up to 20 µl of whole blood per time point. This procedure was found to cause minimal stress to the mice and a maximum of 180 µl of whole blood could be collected for 9 time points over a 3 h time period. Furthermore, following centrifugation and isolation of plasma, a small volume (3 µl) was found to be sufficient for LC-MS/MS quantification of multiple CYP probe drugs and corresponding metabolites under optimal MS conditions ( Table 1 ). Calibrators fell within 15% variation were included to generate a calibration curve for each analyte, and all calibration curves showed excellent linearity (R 2 ≥ 0.99) within the calibration ranges (Table 1) . This LC-MS/MS assay provided accurate and precise quantification of both substrates and metabolites, with minimal intra-and inter-day variability (Table 2 ). As such, a complete PK profile was readily obtained after LC-MS/MS analyses of serial plasma samples obtained from single mouse (data not shown; Figures 2 and 3).
Single-Mouse PK Studies on Inhibition Based DDI. To evaluate utility of this single-mouse PK method, we first examined the effects of KTZ and -NF, two known CYP inhibitors, on the PKs of individual CYP probe substrates in mice. The results showed that plasma MDZ concentrations were significantly increased in mice pretreated with KTZ, which was reflected by a two-or threefold increase in both Cmax and AUC0→∞, respectively, lower oral clearance CL/F, and prolonged elimination t1/2 (Table 3) . This was also associated with significantly lower levels of 1'-OH-MDZ in mice pretreated with KTZ ( Figure 2 ; Table 3 concentrations and PK parameters were not significantly affected by -NF pretreatment, with respect to control ( Figure 2 and Table 3 ).
Pretreatment with -NF led to significant higher plasma PHE concentrations in mice (Figure 2 ), and this was reflected by a two-fold increase in AUC and t1/2, as well as reduction in clearance by one-half (Table 3) . Consistently, plasma APAP concentrations were significantly lower in mice pretreated with -NF (Figure 2 ), which was also indicated by significantly lower Cmax and AUC0→∞ values (Table 3) . Interestingly, plasma PHE concentrations in KTZ-treated mice showed a general decrease as compared to control (Figure 2 ), reflected in a significantly decreased Cmax and AUC0→∞ and increased apparent volume of distribution Vz/F (Table 3) . Nevertheless, mouse plasma APAP concentrations were not affected by KTZ treatment.
As expected, neither KTZ nor -NF treatment had significant impact on mouse plasma DXM concentrations and PK parameters ( Figure 2 and Table 3 ). However, plasma DXO concentrations were significantly lower in KTZ-treated mice, particularly at earlier time points (Figure 2 ), which was indicated by lower Cmax and AUC0→∞ values (Table 3 ). In addition, -NF treatment did not alter DIC and CLZ PK in mice, whereas KTZ surprisingly caused a significant higher systemic exposure to DIC and CLZ ( Figure 2 and Table 3 ). Inhibition of DIC and CLZ clearance was also associated with lower levels of exposure to their metabolites, 4'-OH-DIC and 6-OH-CLZ, respectively, in KTZ-treated mice ( Figure 2 and Table 3 ).
Single-Mouse PK Studies on Induction Based DDI. We further employed this single-mouse PK method to investigate the effects of PCN and 3-MC, two known CYP inducers, on the PKs of (Table 4) . Surprisingly, plasma unconjugated 1'-OH-MDZ concentrations were not increased but decreased by almost 10-fold at later time points in PCN-treated mice, leading to a 6-fold lower AUC0→∞ and 2-fold lower t1/2
value. In addition, pretreatment of 3-MC significantly decreased systemic exposure to MDZ as compared to the control, whereas the degrees of change in PK parameters such as Cmax, AUC0→∞, and CL/F were reduced when compared to PCN treatment ( Figure 3 and Table 4 ).
Compared to the control, pretreated with 3-MC remarkably reduced plasma PHE concentrations in mice, whereas PCN showed minimal effects ( Figure 3 ). In particular, plasma PHE concentrations in 3-MC-treated animals were reduced by approximately 10-fold at all time points, and then fell below the lowest limit of quantification (Table 1) at 45 minutes compared with 60 minutes for control and PCN-treated groups, similar to the observation for MDZ in PCN-treated animals ( Figure 3 ). As such, there were 6-and 33-fold decreases in Cmax and AUC0→∞ values in 3-MC-treated mice (Table 4) , respectively. Likewise, plasma unconjugated APAP concentrations were reduced in both PCN-and 3-MC-treated animals with respect to control, although to a slightly greater degree in 3-MC-treated mice ( Figure 3 and Table 4 ).
In addition, pretreatment of PCN and 3-MC significantly reduced plasma DXM, DIC, and CLZ concentrations in mice (Figure 3) , despite that to a lower degree than the effects of PCN on MDZ or 3-MC on PHE. This was also manifested by modest changes of PK parameters including the decrease of Cmax and AUC0→∞ values, as well as the increase of CL/F values (Table 4) . However, the effects of PCN and 3-MC on unconjugated metabolite levels were relatively complex ( Figure   3 ). Firstly, DXO concentrations were lower in PCN-and 3-MC-treated mice at all time points.
Secondly, 4-OH-DIC concentrations were generally lower in 3-MC-treated mice at all time points, whereas they were higher in PCN-treated mice at earlier stage (0-30 min) and much lower at later stage (30-180 min). Thirdly, PCN treatment led to the production of significantly higher levels of plasma 6-OH-CLZ concentrations in mice, while 3-MC showed minimal influence. These effects were consistently reflected in the changes of corresponding PK parameters such as Cmax, AUC0→∞, and t1/2 (Table 4) . (Table 5) , pre-treatment of miR-34a had no or minimal effects on the PK of PHE, DXM and CLZ as well as their corresponding metabolites, whereas a modest impact on the PK of MDZ and DIC. In particular, the AUC0→∞ of MDZ was 60% higher in mice treated with miR-34a than the control, while its elimination t1/2 and primary PK parameters were unaffected. Furthermore, there was no difference in 1'-OH-MDZ PK in mice treated with miR-34a and control RNA. Similarly, a higher Cmax of DIC was observed in mice following miR-34a pre-treatment (Figure 4 ), leading to a 10% higher exposure (AUC0→∞) which was rather not statistically significant (Table 5) . Likewise, the PK of metabolite 4'-OH-DIC did not differ in mice treated with miR-34a and control RNA. These findings indicated that miR-34a seemed to have a marginal (<50%) impact on the PK of CYP probe drugs in mice as compared to control RNA.
Effects of Biologic miR-34a
This article has not been copyedited and formatted. The final version may differ from this version. The levels of precursor and mature miR-34a were found to be increased by approximately 10-and 80-fold, respectively, in mouse livers treated with biologic miR-34a prodrug ( Figure 5A ), which indicate hepatic accumulation of pre-miR-34a and production of mature miR-34a. Additionally, time-dependent substrate depletion was found to be minimally altered by liver microsomes prepared from the mice treated with miR-34a agent, as compared to the control ( Figure 5B ).
Notably, DXM depletion (CLint) was attenuated by approximately 30% in liver microsomes derived from miR-34a-treated mice. Finally, the depletion of DIC and CLZ depletion was revealed to be minimal in mouse liver microsomes prepared from both groups ( Figure 5B ), and both were indistinguishable from the NADPH-null reaction controls (data not shown), which agree with their metabolic stabilities in liver microsomes.
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Discussion
With the development of new carriers for the delivery of nucleic acids, many RNA agents have entered clinical trials as drug candidates . Because some miRNAs regulate genes underlying drug metabolism and disposition (Yu, 2009; Ingelman-Sundberg et al., 2013; Yokoi and Nakajima, 2013; Yu et al., 2016) , for safety reasons, it is essential to evaluate possible DDI in vivo. Recently, our group has engineered a biologic miR-34a prodrug whose mechanistic actions on target gene expression and xenograft tumor progression have been documented Zhao et al., 2015; Zhao et al., 2016) . In the present study, we elucidated the effects of This single-mouse PK approach involves a simple (non-)terminal, manual serial microsampling procedure whereas it requires a sensitive and accurate LC-MS/MS analytical assay. Tail vein blood collection has been proved to be a reliable means for PK studies in rodents. A thorough comparison of PKs of six marketed drugs in rats using tail vein, cannula and retro-orbital bleeding methods demonstrated that there were no or minor differences in PK properties among these blood sampling methods (Hui et al., 2007) . Although one study reported statistically significant differences in gabapentin PK parameters (e.g., oral bioavailability: 46.82 ± 19.45% versus 61.54 ± 21.23%) in rats for manual and automated blood sampling methods (Aryal et al., 2011) and the latter procedures could be less stressful to mice (Teilmann et al., 2014) , the actual 1.3-fold difference was rather marginal. Most importantly, the plasma drug concentrations versus time curves and estimated PK parameters using this single-mouse PK approach were equally or less variable than those studies using "giant rat" models (Granvil et al., 2003; Shen et al., 2011; Jiang et al., 2013) , and variabilities shown in single-mouse PK studies should represent true differences among individual subjects.
The robustness and application of this single-mouse PK approach is demonstrated by the degrees of mechanistic DDIs between selective CYP inhibitors/inducers and corresponding CYP probe drugs in CD-1 mice. Supporting this, we found that pretreatment of -NF led to a 2.3-fold increase of systemic exposure to PHE, and pretreatment of 3-MC resulted in a 33-fold decrease of exposure to PHE, which are in general agreement with those values identified using rat models (Table 7) while variable drug dosing regimens and animal models may provide some explanations for interstudy variations. The 2.8-fold increase of systemic exposure to MDZ in a single dose of KTZtreated CD-1 mice revealed in the present study is also close to the 3.3-fold increase defined in FVB/N mice (Granvil et al., 2003) , given some rather minor differences in the stains of mice, doses of KTZ and MDZ, routes of administration, and dosing interval (Table 7) . Inter-study variations are also obvious for the degrees of DDIs between MDZ and KTZ in humans, where single dose of KTZ showed reasonably less impact on MDZ exposure as compared to multiple doses of KTZ (Table 7) . Furthermore, the sharp change of MDZ exposure (25-fold decrease) in PCN-treated mice defined by single-mouse PK approach in the present study supports the selectivity of PCN to induce murine drug-metabolizing enzymes via the activation of murine pregnane X receptor (PXR) and the critical role of intestinal enzymes in the control of PK of orally administered MDZ (McCrea et al., 1999; Tsunoda et al., 1999; Granvil et al., 2003; Lam et al., 2003; Pang et al., 2011) . Finally, as Phase 2 conjugation metabolites are not monitored using this assay, a significant decrease rather than increase in plasma 1'-OH-MDZ concentration was observed in mice administered PCN. This is most likely explained by further conjugations of 1'-OH-MDZ, as mouse UDP-glucuronosyltransferases are inducible following PCN-mediated activation of PXR (Buckley and Klaassen, 2009 ).
The effects of CYP inducers (PCN and 3-MC), as well as CYP inhibitors (KTZ and -NF), on the PK properties of parent probe drugs (e.g., MDZ and PHE) revealed in the present study not only highlights the importance of corresponding murine Cyp enzymes in the metabolism of these drugs but also illustrates some species differences. For example, lower levels of DDI between KTZ and MDZ in mice than humans (Table 7) may be in part due to significant contribution of Cyp2c enzymes to MDZ 1'-hydroxylation in mice (Perloff et al., 2000) . In addition, we observed an approximately equal level of decrease in APAP exposure in KTZ-and -NF-treated mice, whereas substrate drug PHE concentrations were decreased in KTZ-treated mice and increased in -NFtreated mice. Likewise, nearly equal significant decrease in APAP exposure was found in both PCN-and 3-MC-treated mice, whereas PHE concentrations were only decreased in 3-MC-treated mice. While the exact mechanisms are unknown, the decrease in APAP may be partially due to complex changes of Phase 2 conjugations following PHE O-deethylation, as well as the involvement of various Cyp enzymes in APAP metabolism (Patten et al., 1993; Zaher et al., 1998) .
The observed increase in the exposure to DIC by KTZ (Figure 2 ) may be interpreted by the fact that DIC is oxidized not only by Cyp2c enzymes but also other CYP isoforms including Cyp3a in mice (Tang et al., 1999; Scheer et al., 2012) . In addition, DXO formation was decreased about 2-This article has not been copyedited and formatted. The final version may differ from this version. fold in KTZ-treated mice and DXM PK were coincidentally altered, which may reflect a modest inhibition of murine DXM O-demethylase Cyp2d enzymes by KTZ (Yu and Haining, 2006) .
Using this single-mouse PK approach and a biologic miR-34a agent, rather than synthetic miRNA reagents bearing extensive artificial modifications (Duan and Yu, 2016; Ho and Yu, 2016) , we were able to identify the somewhat limited effects of miR-34a on PK of individual CYP probe drugs; this was also supported by findings from in vitro metabolism study. Compared to control RNA treatment, miR-34a either did not affect (e.g., DXM, PHE and CLZ exposure) or led to minor (<50%) changes (e.g., MDZ and DIC). Compared to control, DIC Cmax and MDZ AUC0→∞ values in miR-34a-treated mice were significantly increased (Table 5) , suggesting possible alteration of murine Cyp3a and Cyp2c by miR-34a. This is complementary to studies that found negative correlation between miR-34a and CYP3A4 and 2C19 (Lamba et al., 2014) , as well as miR-34a
targeting of RXRα/NR2B1 (Oda et al., 2014) and Nrf2/NFE2L2 (Huang et al., 2014) by miR-34a.
In addition, the transcription factor HNF4α has been found to be highly conserved between mouse and human species (Boj et al., 2009 ) and miRNA recognition elements have been identified for miR-34a in both human and mouse 3'UTR of HNF4α mRNA (Takagi et al., 2010 ) (three miR-34a
MREs within murine Rxra 3'UTR by TargetScan (http://www.targetscan.org) and miRanda (http://www.microrna.org)).
Our findings from mouse models are also complicated by the presence of species differences in the expression of regulatory factors, and drug-metabolizing enzymes and transporters as well as their functions in processing the drugs. Indeed, the present study found that the formation of both 1'-OH-MDZ or 4'-OH-DIC were not altered in vivo (Table 5) affected in vitro (Table 6 ). These data suggest that miR-34a-induced alterations to MDZ or DIC PK are not manifested in alteration of murine Cyp enzymes. Additionally, DIC and CLZ depletion in mouse liver microsomes ( Figure 5B ) was minimal, which not only supports their metabolic stability in microsomes but also suggests the presence of other mechanisms besides hepatic microsomal metabolism that are responsible for their clearance. As such, the discrepancy between the observed alterations to in vivo PK and in vitro probe drug clearance may be explained by modulation of phase II enzyme or drug transporter genes by miR-34a. Indeed, RXRα, a putative miR-34a target, likely modulates the expression of several glutathione S-transferase isoforms (Dai et al., 2005) , although no similar evidence exists for sulfo-or glucuronosyltransferase enzymes.
In summary, this study established a practical approach to perform single-mouse PK and DDI studies which was employed to demonstrate the remarkable PK DDIs between selective CYP inhibitors/inducers and CYP probe drugs in mice, as well as some species differences. In addition,
we were able to reveal the marginal effects of miR-34a on MDZ, DIC, and DXM PK in mice.
However, further research is required to confirm the findings, particularly in a more translational humanized mouse model. 
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This article has not been copyedited and formatted. The final version may differ from this version. pierced at an angle similar to intravenous injection into the tail vein. The plunger of the syringe was slightly aspirated and needle was quickly removed and a large drop of blood was allowed to form, using pressure to draw blood to the site of puncture if necessary. (B) The drop of blood was quickly collected using a 10 l pipette tip (previously coated with 6% EDTA), transferred to a microcentrifuge tube containing 1 l 6% EDTA, and placed on ice until centrifugation. Table 3 . Effects of KTZ and -NF on pharmacokinetic parameters of individual drugs and metabolites. Data were fit to a noncompartmental PK model. ‡ Given incomplete data points because some were below quantification limits, a sparse data model was used. Values represent mean SD generated from 6 mice. ***p < 0.001, **p < 0.01, and *p < 0.05 when compared to control (Oneway ANOVA with Bonferroni post-hoc tests). Table 4 . Effects of PCN and 3-MC on pharmacokinetic parameters of individual drugs and metabolites. Data were fit to a noncompartmental PK model. ‡ Given incomplete data points because some were below quantification limits, a sparse data model was used.
MDZ
Not determined (n.d.) due to insufficient data points representing the elimination phase. Values represent mean SD generated from 6 mice. ***p < 0.001, **p < 0.01, and *p < 0.05 when compared to control (One-way ANOVA with Bonferroni post-hoc tests). 

